A new report shows barely a quarter of board members cite CEO succession as a top priority.

Medtronic announced a spin-off of its diabetes business in May, which will be completed in 2026. Read more on MDT stock here.

Although the company's advancements have influenced contemporary healthcare, its stock presents a more cautious narrative ...

While Medtronic has struggled to keep up with the broader market over the past year, analysts remain fairly upbeat on its ...

Medtronic's separation of its Medtronic Diabetes unit into a publicly traded company named MiniMed will be a new beginning ...

Medtronic also disclosed severance for a former SVP, and pay for its median employee, and a slight decrease in global ...

All of those factors make Medtronic an excellent pick for income-seeking investors. It should continue rewarding shareholders ...

Medtronic's decade-long underperformance stems from stagnant revenue growth, declining margins, and inconsistent returns on ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and ...

Medtronic has long been a committed dividend payer -- and grower. It's been turning itself around after a slump. There's ...

Orchestra BioMed announced today that it completed strategic transactions and equity offerings worth an expected $111.2 ...

Shares of Medtronic PLC MDT slipped 1.53% to $90.24 Thursday, on what proved to be an all-around poor trading session for the ...